Biotech is one of the few areas of the stock market where a company can look completely different by the end of a single trading day.
A positive clinical trial can suddenly turn an overlooked drug into a serious commercial opportunity. An FDA approval can move a company from years of research into an actual product launch. The opposite is also true, which is why biotech investing comes with much more risk than simply buying a profitable company and waiting for earnings to grow.
For this list, we weren’t looking for the biggest biotech companies. We were looking for clear catalysts coming this fall, enough cash to reach them and where success could still change the valuation.
Here are the three that stood out.
| Company | Ticker | Price | Market Cap | Main Fall Catalyst |
|---|---|---|---|---|
| Alumis | ALMS | $24.46 | $3.1B | Phase 2b lupus results |
| Savara | SVRA | $5.37 | $1.36B | FDA decision Nov. 22 |
| Entrada Therapeutics | TRDA | $7.28 | $307M | Duchenne data in October |
Market data as of August 18, 2026.
1. Alumis: Can one successful drug become much bigger?
Alumis Inc. (Nasdaq: ALMS) is developing treatments for autoimmune diseases, and its most important drug is envudeucitinib.
The drug has already delivered encouraging late-stage results in plaque psoriasis. In its longer-term Phase 3 study, 54% of patients achieved completely clear skin after 48 weeks, and Alumis plans to submit the drug to the FDA in the fourth quarter of 2026.
That already gives Alumis something many biotech companies don’t have: evidence from a large late-stage program that its main drug works.
Now the company gets to answer a much bigger question.
Alumis is testing envudeucitinib in lupus, a difficult autoimmune disease that can affect the skin, joints, kidneys and other organs. Its LUMUS Phase 2b study enrolled 408 patients, with results expected in the third quarter.
If the lupus trial succeeds, investors may stop viewing envudeucitinib as mainly a psoriasis drug. It could begin looking like a drug that works across several autoimmune diseases, which would considerably expand the opportunity.
Alumis also finished June with about $502 million in cash and marketable securities, giving it enough capital to keep developing the pipeline without an immediate financing hanging over the stock.
The risk: Alumis is already worth more than $3 billion, so expectations aren’t low. Lupus is also notoriously difficult to treat in clinical trials. Success in psoriasis does not guarantee success here.
Still, we think Alumis offers an attractive combination: a drug that has already worked, followed by a catalyst that could make the opportunity much larger.
2. Savara: November 22 is the date that matters
Savara Inc. (Nasdaq: SVRA) has an unusually simple fall setup.
The company is waiting for the FDA to decide whether to approve MOLBREEVI, its inhaled treatment for autoimmune pulmonary alveolar proteinosis, or autoimmune PAP.
The FDA decision is currently scheduled for November 22, 2026.
Autoimmune PAP is a rare lung disease where material builds up inside the lungs and makes it harder for patients to transfer oxygen normally.
Savara has already completed the big trial.
Its 164-patient Phase 3 IMPALA-2 study met its primary endpoint, showing a statistically significant improvement in lung function compared with placebo. The study also showed improvement in a measure of respiratory quality of life.
That means the main question this fall isn’t whether the Phase 3 trial works. We already have that answer.
The question is whether the FDA believes the total package is strong enough for approval.
Approval would completely change Savara’s position. It would move from being a clinical-stage biotech into a company preparing to sell its first product.
Savara also had approximately $173 million in cash and short-term investments at the end of June. The company says another up to $150 million of non-dilutive capital could become available upon FDA approval.
The risk: FDA decisions are binary. A rejection, another delay or an unexpected regulatory issue could hit the stock quickly.
At roughly $1.36 billion, Savara is not trading like nobody expects approval. But November 22 still represents a genuine company-changing event.
Of the three stocks on this list, Savara has the clearest catalyst.
3. Entrada Therapeutics: The smallest name could have the biggest swing
Entrada Therapeutics Inc. (Nasdaq: TRDA) is the smallest and most speculative company on our list.
At around $7.28 per share, Entrada is valued at roughly $307 million.
The company is developing genetic medicines for Duchenne muscular dystrophy, a devastating muscle-wasting disease caused by mutations that prevent patients from producing enough functional dystrophin protein.
Entrada is trying to help the body produce more usable dystrophin through a technology known as exon skipping.
We don’t need to make that complicated.
The basic idea is to skip over a damaged section of the gene so the body can produce a shorter but potentially useful version of the missing protein.
The catalyst we’re watching is October 2026, when Entrada expects to report the first patient data from its ENTR-601-45 Phase 1/2 study. The first cohort enrolled eight patients, and an independent monitoring committee has already allowed the trial to move into the higher-dose cohort without changing the protocol.
Entrada’s market value is only slightly above the cash and investments sitting on its balance sheet. The company reported about $223 million in cash, cash equivalents and marketable securities at the end of June.
That doesn’t automatically make the stock cheap. Entrada is spending heavily on clinical development, and that cash will fall.
But it does show how little value the market is currently placing on the pipeline.
If the October data show that Entrada can safely deliver its therapy into muscle and produce a convincing biological effect, investors may begin giving more value to the entire platform—not just one drug.
The risk: these are very early clinical studies with tiny patient groups. Entrada is nowhere near proving that its drugs will ultimately become approved treatments.
That makes TRDA our highest-risk pick.
It may also have the most room for investor expectations to change.
Biotech comes down to what changes next
These aren’t three versions of the same investment.
Alumis has the strongest clinical foundation and is trying to prove that one successful drug can work across a much broader range of autoimmune diseases.
Savara is waiting for an FDA decision that could turn its lead drug into a commercial product.
Entrada is the early-stage bet, where a small October study could begin proving—or disproving—the value of an entire technology platform.
That is what we want from a fall biotech watchlist.
Not simply three companies with interesting science.
We want a clear event that can change what the company is worth.
The tradeoff is that biotech works both ways. Failed trials and regulatory setbacks can erase years of expected value almost overnight.
But heading into fall, ALMS, SVRA and TRDA each have something specific in front of them that could leave the company in a very different position by year-end.
That makes all three worth watching.
Explore More Stories in Health
Disclaimer
Wall Street Access is an independent financial publisher. Wall Street Access is not a financial advisor. No company mentioned has compensated Wall Street Access for the preparation, publication or distribution of this article. This content is provided for informational and educational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Investing involves risk, including the possible loss of principal. Prices, market capitalizations, financial figures and other market data are based on information available as of the date and time of publication and may change without notice. Information is drawn from public sources believed to be reliable but is not guaranteed to be complete or accurate. Opinions and expectations expressed are our own and may change as new information becomes available. Readers should conduct their own due diligence and contact a licensed financial professional before making any investment decision. Past performance does not guarantee future results. Any material ownership interest or conflict of interest, where applicable, will be disclosed separately.
